Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • M.D., Ohio State University 1982
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Isakoff, S. J., J. Tabernero, L. R. Molife, J. -. C. Soria, A. Cervantes, N. J. Vogelzang, M. R. Patel, et al. “Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.” Ann Oncol 31, no. 5 (May 2020): 626–33. https://doi.org/10.1016/j.annonc.2020.02.007.
       Full Text  Link to Item
    • Beeram, M., S. M. Tolaney, J. T. Beck, M. N. Dickler, A. K. Conlin, C. Dees, T. L. Helsten, et al. “A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer.” Annals of Oncology 27 (October 1, 2016): vi556. https://doi.org/10.1093/annonc/mdw435.08.
       Full Text
    • Sequist, L. V., A. Chiang, J. Gilbert, M. Gordon, P. R. Conkling, D. Thompson, J. P. Marcoux, et al. “Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC).” Annals of Oncology 27 (October 1, 2016): vi493. https://doi.org/10.1093/annonc/mdw389.03.
       Full Text
    • Rashidi, Armin, Paul R. Conkling, and Stephen I. Fisher. “Acute promyelocytic leukemia following solid organ transplantation.” Ann Hematol 95, no. 1 (January 2016): 169–71. https://doi.org/10.1007/s00277-015-2524-7.
       Full Text  Link to Item
    • Picozzi, Vincent J., Ramesh K. Ramanathan, Maeve A. Lowery, Allyson J. Ocean, Edith P. Mitchel, Bert H. O’Neil, Michael J. Guarino, et al. “(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.” Eur J Cancer 51, no. 14 (September 2015): 1857–64. https://doi.org/10.1016/j.ejca.2015.06.119.
       Full Text  Link to Item
    • Jotte, Robert M., Daniel D. Von Hoff, Fadi Braiteh, Carlos R. Becerra, Donald A. Richards, David A. Smith, Lawrence Garbo, et al. “An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.” Invest New Drugs 33, no. 1 (February 2015): 148–58. https://doi.org/10.1007/s10637-014-0160-z.
       Full Text  Link to Item
    • Rashidi, Armin, Marc L. Silverberg, Paul R. Conkling, and Stephen I. Fisher. “Thrombosis in acute promyelocytic leukemia.” Thromb Res 131, no. 4 (April 2013): 281–89. https://doi.org/10.1016/j.thromres.2012.11.024.
       Full Text  Link to Item
    • Saltz, Leonard, Suprith Badarinath, Shaker Dakhil, Bryan Bienvenu, W Graydon Harker, George Birchfield, Laurence K. Tokaz, et al. “Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.” Clin Colorectal Cancer 11, no. 2 (June 2012): 101–11. https://doi.org/10.1016/j.clcc.2011.05.006.
       Full Text  Link to Item
    • Robert, Nicholas J., Paul R. Conkling, Mark A. O’Rourke, Paul R. Kuefler, Kristi J. McIntyre, Feng Zhan, Lina Asmar, Yanping Wang, Oluwatoyin O. Shonukan, and Joyce A. O’Shaughnessy. “Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.” Breast Cancer Res Treat 126, no. 1 (February 2011): 101–8. https://doi.org/10.1007/s10549-010-1286-0.
       Full Text  Link to Item
    • Lossos, I., M. D. Craig, M. S. Tallman, R. V. Boccia, P. R. Conkling, C. Becerra, P. B. Komarnitsky, B. L. Hamilton, J. Lewis, and W. H. Miller. “Novel organic arsenic molecule darinaparsin: Development of IV and oral forms.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 8501.
       Link to Item
    • Conkling, P. R., K. L. Patton, Y. A. Hannun, C. S. Greenberg, and J. B. Weinberg. “Sphingosine inhibits monocyte tissue factor-initiated coagulation by altering factor VII binding.” J Biol Chem 264, no. 31 (November 5, 1989): 18440–44.
       Link to Item
    • Conkling, P. R., K. E. Achyuthan, C. S. Greenberg, T. F. Newcomb, and J. B. Weinberg. “Human mononuclear phagocyte transglutaminase activity cross-links fibrin.” Thromb Res 55, no. 1 (July 1, 1989): 57–68. https://doi.org/10.1016/0049-3848(89)90456-8.
       Full Text  Link to Item
    • Conkling, P. R., C. C. Chua, P. Nadler, C. S. Greenberg, E. Doty, M. A. Misukonis, A. F. Haney, R. C. Bast, and J. B. Weinberg. “Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function.” Cancer Res 48, no. 19 (October 1, 1988): 5604–9.
       Link to Item
    • CONKLING, P. R., K. L. PATTON, Y. A. HANNUN, C. S. GREENBERG, and J. B. WEINBERG. “SPHINGOSINE INHIBITS TISSUE FACTOR-INDUCED BLOOD-CLOTTING.” Arteriosclerosis 8, no. 5 (September 1, 1988): A664–A664.
       Link to Item
    • Conkling, P. R., C. S. Greenberg, and J. B. Weinberg. “Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes.” Blood 72, no. 1 (July 1988): 128–33.
       Link to Item
    • Weisberg, L. J., D. T. Shiu, P. R. Conkling, and M. A. Shuman. “Identification of normal human peripheral blood monocytes and liver as sites of synthesis of coagulation factor XIII a-chain.” Blood 70, no. 2 (August 1987): 579–82.
       Link to Item
    • CONKLING, P. R., C. S. GREENBERG, and J. B. WEINBERG. “TUMOR-NECROSIS-FACTOR INDUCES TISSUE FACTOR ACTIVITY IN HUMAN-LEUKEMIA CELL-LINE U937.” Proceedings of the American Association for Cancer Research 28 (March 1, 1987): 400–400.
       Link to Item
    • CONKLING, P. R., C. S. GREENBERG, T. F. NEWCOMB, and J. B. WEINBERG. “CHARACTERIZATION OF COAGULATION-FACTOR XIII (FXIII) IN PERITONEAL-MACROPHAGES AND MONOCYTES FROM NORMAL AND FXIII-DEFICIENT HUMANS.” Journal of Leukocyte Biology 40, no. 3 (September 1, 1986): 267–68.
       Link to Item
    • Conkling, P. R. “Brown blood: understanding methemoglobinemia.” N C Med J 47, no. 3 (March 1986): 109–11.
       Link to Item
    • Klassen, D. K., P. R. Conkling, and A. L. Sagone. “Activation of monocyte and granulocyte antibody-dependent cytotoxicity by phorbol myristate acetate.” Infect Immun 35, no. 3 (March 1982): 818–25. https://doi.org/10.1128/iai.35.3.818-825.1982.
       Full Text  Link to Item

  • Conference Papers

    • Kim, Joseph W., David R. Shaffer, Christophe Massard, Thomas Powles, Lauren Christine Harshman, Fadi S. Braiteh, Paul R. Conkling, et al. “A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 36:187–187. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.187.
       Full Text
    • Beeram, M., S. M. Tolaney, J. T. Beck, M. N. Dickler, A. K. Conlin, C. Dees, T. L. Helsten, et al. “A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer.” In Annals of Oncology, Vol. 27. OXFORD UNIV PRESS, 2016. https://doi.org/10.1093/annonc/mdw435.8.
       Full Text  Link to Item
    • Sequist, L. V., A. Chiang, J. Gilbert, M. Gordon, P. R. Conkling, D. Thompson, J. P. Marcoux, et al. “Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC).” In Annals of Oncology, Vol. 27. OXFORD UNIV PRESS, 2016. https://doi.org/10.1093/annonc/mdw389.3.
       Full Text  Link to Item
    • Becerra, Carlos, Alexander I. Spira, Paul R. Conkling, Stephen Lane Richey, Wahid Tewfik Hanna, Gregory Michael Cote, Rebecca Suk Heist, et al. “A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.” In Journal of Clinical Oncology, 34:9093–9093. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.9093.
       Full Text
    • Goetz, M. P., M. Beeram, T. Beck, A. K. Conlin, E. C. Dees, M. N. Dickler, T. L. Helsten, et al. “Abstract P4-13-25: Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer.” In Cancer Research, Vol. 76. American Association for Cancer Research (AACR), 2016. https://doi.org/10.1158/1538-7445.sabcs15-p4-13-25.
       Full Text
    • Picozzi, Vincent J., Ramesh K. Ramanathan, Maeve A. Lowery, Allyson J. Ocean, Edith P. Mitchell, Bert H. O’Neil, Michael J. Guarino, et al. “Abstract B98: Final results of a randomized phase Ib study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having at least two prior therapies.” In Cancer Research, 75:B98–B98. American Association for Cancer Research (AACR), 2015. https://doi.org/10.1158/1538-7445.panca2014-b98.
       Full Text
    • Becerra, Carlos, Joe Stephenson, Derek J. Jonker, Allen Lee Cohn, Timothy R. Asmis, Tanios S. Bekaii-Saab, Paul R. Conkling, et al. “Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.” In Journal of Clinical Oncology, 33:4069–4069. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.4069.
       Full Text
    • Jonker, Derek J., Scott Andrew Laurie, Gregory Michael Cote, Keith Flaherty, Charles S. Fuchs, Rashmi Chugh, David C. Smith, et al. “Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.” In Journal of Clinical Oncology, 33:3615–3615. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.3615.
       Full Text
    • Tolaney, Sara M., Muralidhar Beeram, J Thaddeus Beck, Alison Katherine Conlin, Elizabeth Claire Dees, Maura N. Dickler, Teresa L. Helsten, et al. “A phase Ib study of abemaciclib with therapies for metastatic breast cancer.” In Journal of Clinical Oncology, 33:522–522. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.522.
       Full Text
    • Picozzi, Vincent J., Ramesh K. Ramanathan, Maeve Aine Lowery, Allyson J. Ocean, Edith P. Mitchell, Bert H. O’Neil, Michael J. Guarino, et al. “Feasibility and results of a randomized phase Ιb study of fractionated ⁹⁰Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies.” In Journal of Clinical Oncology, 32:4026–4026. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.4026.
       Full Text
    • Richards, Donald A., Fadi S. Braiteh, A. A. Garcia, Crystal Shereen Denlinger, Paul R. Conkling, William Jeffery Edenfield, Stephen Patrick Anthony, et al. “A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors.” In Journal of Clinical Oncology, 32:651–651. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.651.
       Full Text
    • Jotte, R., P. R. Conkling, C. Reynolds, C. Shah, M. Galsky, L. Klein, J. F. Fitzgibbons, R. McNally, J. W. Oliver, and M. Renschler. “9120 Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial.” In European Journal of Cancer Supplements, 7:540–41. Elsevier BV, 2009. https://doi.org/10.1016/s1359-6349(09)71833-6.
       Full Text
    • Lossos, I., M. D. Craig, M. S. Tallman, R. V. Boccia, P. R. Conkling, C. Becerra, P. B. Komarnitsky, B. L. Hamilton, J. Lewis, and W. H. Miller. “Novel organic arsenic molecule darinaparsin: Development of IV and oral forms.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
       Link to Item
    • Jotte, R. M., P. R. Conkling, C. Reynolds, A. R. Allen, and J. W. Oliver. “A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy.” In Journal of Clinical Oncology, Vol. 26. AMER SOC CLINICAL ONCOLOGY, 2008.
       Link to Item
    • Cohen, S. J., M. M. Zalupski, M. R. Modiano, P. R. Conkling, Y. Z. Patt, P. Davis, R. T. Dorr, M. L. Boytim, and E. M. Hersh. “A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity.” In Journal of Clinical Oncology, 26:4619–4619. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.4619.
       Full Text
    • Robert, N. J., P. R. Conkling, P. R. Kuefler, K. J. McIntyre, F. Zhan, L. Asmar, Y. Wang, O. O. Shonukan, and J. O’Shaughnessy. “Results of a phase II study of pemetrexed as first-line chemotherapy for advanced or metastatic breast cancer.” In Journal of Clinical Oncology, 26:1073–1073. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.1073.
       Full Text
    • CONKLING, P. R., and A. L. SAGONE. “METABOLIC CHARACTERISTICS OF HUMAN ALVEOLAR MACROPHAGE-MEDIATED ANTIBODY-DEPENDENT CYTO-TOXICITY.” In Clinical Research, 30:A314–A314. SLACK INC, 1982.
       Link to Item
    • CONKLING, P. R., and A. L. SAGONE. “EFFECTS OF ANTIBODY (AB) ON LYSIS OF CHICKEN ERYTHROCYTES (CRBC) BY HUMAN ALVEOLAR MACROPHAGES (AMS) COMPARED TO HUMAN POLYMORPHONUCLEAR CELLS (PMNS) AND MONOCYTES (MOS).” In Clinical Research, 29:A738–A738. SLACK INC, 1981.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.